In the ever-evolving world of biotechnology, the unexpected can often be the catalyst for significant change. This is the case for the Duchenne muscular dystrophy (DMD) community following the tragic death of a patient linked to Sarepta Therapeutics’ gene therapy, Elevidys. This event, as dissected in a recent report by Jason Mast and colleagues at […]